Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

FDA Approves Jaypirca for Relapsed/Refractory Mantle Cell Lymphoma

January 27th 2023

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.

Avoiding Unavoidable Carcinogens

January 4th 2023

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Patients With Mantle Cell Lymphoma Continue to Respond to Tecartus Three Years Later

June 22nd 2022

Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.

‘A New Benchmark’ Treatment Option for Older Patients with Mantle Cell Lymphoma

June 3rd 2022

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

Trial Launches to Study a New Drug for B-Cell Malignancies

May 20th 2022

NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

'Death Doulas' Help Patients With Cancer Face Their End of Life With Courage and Meaning

May 18th 2022

Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.

Two-Drug Combo Elicits Similar Outcomes to Standard of Care in Young Patients With Non-Hodgkin Lymphoma

May 11th 2022

The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.

Pharma Company Stops Patient Enrollment in Ewing Sarcoma Trial to Prioritize Development of a Blood Cancer Drug

April 15th 2022

The plan, according to the San Diego-based pharmaceutical company, is to launch a phase 3 trial to analyze the safety and efficacy of a novel drug in mantle cell lymphoma in the second half of 2022.

Now That Telemedicine is a Mainstay in Cancer Care, One Expert Notes When Patients Should Opt for Virtual Appointments

April 6th 2022

The COVID-19 pandemic brought on a huge surge in the use of telemedicine for cancer care, but now as the pandemic is slowing down, an expert said that there are certain times when telemedicine will do, while other situations warrant an in-person visit with the doctor.

CAR-T Cell Therapies Offer ‘An Opportunity for Majority of Patients’ With Lymphoma to Be Treated

March 14th 2022

Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.

CAR-T Cell Therapies Provide Patients With Mantle Cell and Follicular Lymphoma a ‘One and Done’ Treatment Option, Expert Says

March 2nd 2022

CAR-T cell therapies offer patients with lymphoma a chance for long-term remission, but none have yet to receive a greenlight from the FDA as a first line of treatment.

Addition of Ofatumumab to Aggressive Chemotherapy Regimen Yields High Response Rates in Newly Diagnosed Mantle Cell Lymphoma

March 2nd 2022

Treatment with ofatumumab plus an aggressive regimen of chemotherapies resulted in a response rate of more than 80% in patients with newly diagnosed mantle cell lymphoma.

Experimental Lymphoma Drug Shows ‘Robust Clinical Activity,’ Researchers Say

February 25th 2022

Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.

My Oncologist Gave Me a Pseudo-Medication Taper That Made Me Feel Like I Was Losing Control

February 16th 2022

In the midst of my treatment for mantle cell lymphoma, I had to suffer through the feeling of wanting to crawl out of my own skin when my oncologist gave me a medication tapering plan that was not gradual enough.

Decades of MCL Treatment Advancements a ‘Godsend’ for Patients

February 14th 2022

From the use of BTK inhibitors to maintenance therapy, an expert highlights how the treatment landscape of mantle cell lymphoma has drastically changed for the better in recent decades.

Supportive Care and Palliative Care May Improve Outcomes in Patients Receiving CAR-T Cell Therapy

February 14th 2022

Supportive care should be implemented promptly after patients receive CAR-T cell therapy, but as one expert notes, patients with cancer are often referred for this care too late.

Clinical Trial Testing Effectiveness of LOXO-305 in Mantle Cell Lymphoma Now Open to Patients

February 9th 2022

A phase 3 trial evaluating the safety and efficacy of the BTK inhibitor LOXO-305 in patients with previously treated mantle cell lymphoma is now open to patients across more than a dozen states.

Prophylactic Monoclonal Antibodies Recommended to Protect Certain Patients With Cancer From COVID-19

January 11th 2022

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

Third Full Dose of COVID-19 Vaccine Increases Antibody Response in Patients with Blood Cancers

December 23rd 2021

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

Side Effects, Costs Can Be ‘Game Changers’ in Deciding MCL Treatment

November 19th 2021

With three BTK inhibitors approved for treatment of mantle cell lymphoma, patients and providers should consider side effects and insurance coverage before deciding on a drug.

FDA Will Review New Drug to Treat Non-Hodgkin Lymphoma

November 1st 2021

The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.

'The Future is Promising' For The Treatment of a Subtype of Non-Hodgkin Lymphoma

October 18th 2021

More selective BTK inhibitors like Brukinsa may give patients with mantle cell lymphoma who progressed on prior therapies another option with potentially fewer and more manageable side effects.

Mantle Cell Lymphoma Treatment in the Era of COVID-19

September 17th 2021

After determining an aggressive or non-aggressive treatment approach to mantle cell lymphoma, patients and clinicians must then discuss COVID-19 vaccine efficacy when determining a maintenance treatment strategy.

Tecartus for MCL: Expert Reflects After a Year Since FDA Approval

September 15th 2021

Tecartus was the first CAR-T cell therapy to be approved for the treatment of recurrent mantle cell lymphoma. Now, more than a year after its approval, a doctor discusses his experience prescribing the drug.

Third Dose of COVID-19 Vaccine May Increase Protection in Immunocompromised Patients

August 19th 2021

Patients who are immunocompromised, such as patients with blood cancers, may get the boosted immunity needed to reduce their risk for contracting COVID-19 and hospitalization for compilations related to the virus.

Expert Explains Prognosis Indicators, Treatment Plans in MCL

August 4th 2021

Some patients with mantle cell lymphoma can opt for a wait-and-watch approach, while others will need more aggressive treatment.

Patients With Blood Cancer Less Likely to Produce COVID-19 Antibodies After Vaccination

July 26th 2021

About 25% of patients with blood cancer did not produce antibodies after being vaccinated against COVID-19.

Choosing a BTK Inhibitor for MCL: Consider Side Effects and Insurance Coverage

July 16th 2021

When patients with mantle cell lymphoma are discussing the use of a BTK inhibitor, they must consider what their insurance will cover, as well as current health complications and potential side effects.

‘No One-Size-Fits-All’ First-Line Treatment for Mantle Cell Lymphoma

July 14th 2021

Patients can now prioritize whether durable responses to treatment or avoiding certain side effects are more valuable to them.

When MCL Relapses Early, Consider Different Treatment Options

July 13th 2021

Patients with mantle cell lymphoma whose disease relapses within a year and a half of transplant tend to have worse outcomes and may want to consider new treatment regimens.

NEXT PAGE
PREVIOUS PAGE